Patents Assigned to The Kenneth S. Warren Institute, Inc.
-
Publication number: 20130102530Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.Type: ApplicationFiled: June 13, 2012Publication date: April 25, 2013Applicant: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 8404226Abstract: Methods and compositions are provided for treating a mammal having inflammation by protecting or enhancing a responsive cell, tissue, organ or body part exhibiting or associated with the inflammation, by systemic or local administration of a composition comprising a tissue protective cytokine. The invention also encompasses combination treatments comprising administering a composition comprising a tissue protective cytokine of the invention and administering at least one anti-inflammatory or least one immunomodulatory agent.Type: GrantFiled: July 3, 2003Date of Patent: March 26, 2013Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 7767643Abstract: Methods and compositions are provided for protecting or enhancing an erythropoietin-responsive cell, tissue, organ or body part function or viability in vivo, in situ or ex vivo in mammals, including human beings, by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin or a modified erythropoietin.Type: GrantFiled: June 26, 2002Date of Patent: August 3, 2010Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 7718363Abstract: The present invention is directed methods for identifying compounds that have a tissue protective activity using a heteromultimer receptor complex that mediates the tissue protective activities. The complex consists of at least one EPO-R in complex with at least one ?c Receptor. These compounds used in the assays to identify tissue protective compounds include, but are not limited to, small molecules and biologics. The compounds identified using these assays can be used to treat various conditions of the central and peripheral nervous systems as well as those of other erythropoietin-responsive or excitable cells, tissues, and organs.Type: GrantFiled: September 30, 2003Date of Patent: May 18, 2010Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Thomas Coleman
-
Patent number: 7645733Abstract: A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.Type: GrantFiled: September 29, 2004Date of Patent: January 12, 2010Assignees: The Kenneth S. Warren Institute, Inc., Warren Pharmaceuticals, Inc.Inventors: Michael Brines, Anthony Cerami, Thomas Coleman, Osman Yilmaz
-
Publication number: 20080305990Abstract: The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 ?g/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay. Additionally, the invention is related to pharmaceutical compositions containing carbamylated erythropoietins of the invention and the use of the pharmaceutical compositions for the treatment of conditions and diseases of excitable tissues.Type: ApplicationFiled: July 1, 2005Publication date: December 11, 2008Applicant: The Kenneth S Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Hand, Qiao-wen Xie
-
Patent number: 7410941Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.Type: GrantFiled: November 21, 2000Date of Patent: August 12, 2008Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 7345019Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.Type: GrantFiled: November 21, 2000Date of Patent: March 18, 2008Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Patent number: 7309687Abstract: Methods and compositions are provided for protecting or enhancing excitable tissue function in mammals by systemic administration of an erythropoietin receptor activity modulator, such as erythropoietin, which signals via an EPO-activated receptor to modulate the function of excitable tissue. Excitable tissues include central neuronal tissues, such as the brain, peripheral neuronal tissues, retina, and heart tissue. Protection of excitable tissues provides treatment of hypoxia, seizure disorders, neurodegenerative diseases, hypoglycemia, and neurotoxin poisoning. Enhancement of function is useful in learning and memory. The invention is also directed to compositions and methods for facilitating the transport of molecules across endothelial cell tight junction barriers, such as the blood-brain barrier, by association of molecules with an erythropoietin receptor activity modulator, such as an erythropoietin.Type: GrantFiled: November 21, 2000Date of Patent: December 18, 2007Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami
-
Publication number: 20070129293Abstract: A method of treating, preventing, delaying the onset, and/or reducing the effects of proinflammatory cytokines in conditions including, but not limited to, sepsis, adhesion formation, wounds, organ failure, chronic disease, general inflammatory conditions resulting from infection, scarring resulting from injury and incisions, and combinations thereof.Type: ApplicationFiled: September 29, 2004Publication date: June 7, 2007Applicants: The Kenneth S. Warren Institute, Inc., Warren Pharmaceuticals, Inc.Inventors: Thomas Coleman, Osman Yilmaz
-
Patent number: 6531121Abstract: Methods and compositions are provided for protecting or enhancing erythropoietin-responsive cell, tissue, organ and bodily part function and viability in vivo, in situ or ex vivo in mammals including human beings by systemic or local administration of an erythropoietin receptor activity modulator, such as an erythropoietin:Type: GrantFiled: December 29, 2000Date of Patent: March 11, 2003Assignee: The Kenneth S. Warren Institute, Inc.Inventors: Michael Brines, Anthony Cerami, Carla Cerami